Authors:

Damela San Martín

University of Bio-Bio, Fernando May Campus, Chile

Abstract:

Hepatitis C virus (HCV) represents a world burden on health care that affects over a hundred and fifty million folks worldwide. within the past, HCV genotype three was thought of troublesome to treat relative to different genotypes. Genotype three has been related to a better rate of complications, as well as malady} disease, fibrosis, malignant hepatoma and mortality. However, with the appearance of first- and second-generation direct-acting antivirals, genotype three is treated effectively. to boot, these new medicine square measure well tolerated by patients and have considerably fewer facet effects compared to antiviral agent and interferon-based regimens. However, whereas nice strides are created in overcoming biological barriers, our next challenge lies in overcoming economic and monetary obstacles if we have a tendency to square measure to eradicate HCV genotype three. Herein, we have a tendency to review the clinical options related to HCV genotype three, current and rising treatment regimens, and challenges related to treatment.

Keywords:
Hepatitis C, genotype 3, sustained viral response, direct acting antivirals, treatment.

Citation:

Damela San Martín. Clinical aspects of genotype 3 hepatitis C virus, present and emerging viral inhibitors, and future difficulties Japanese Journal of Gastroenterology 2022.